Company: SHPH
Filing Date: 2025-01-24
Form Type: 424B3
Source: 0001493152-25-003508
Chunk: 117

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-24
Form: 424B3
Chunk 117
---
 | (5,581,147 | ) |     |              | (2,666,411 | ) |     |        | (2,914,736 | ) |     |   | 109 | %  |
| Cash used in investing activities                  |     |                          | (2,829,723 | ) |     |              |          — |   |     |        | (2,829,723 | ) |     |   | 100 | %  |
| Cash provided by financing activities, as restated |     |                          |  2,570,083 |   |     |              | 10,578,865 |   |     |        | (8,008,782 | ) |     |   | (76 | )% |
| Cash and cash equivalents on hand                  |     |                          |  2,576,416 |   |     |              |  8,417,203 |   |     |        | (5,840,787 | ) |     |   | (69 | )% |

| 75 |

Cash Flows from Operating Activities

To date, we have not generated positive cash flows from operating activities. For the year ended December 31, 2023, net cash flows used in operating activities was $5.6 million, primarily consisting of a net loss of $6.6 million, increased by a gain on change in derivative liabilities of $2.2 million, offset by amortization of debt discount of $2.1 million, loss on settlement of convertible debt of $0.5 million, accrued interest settled with common stock of $0.3 million, stock-based compensation of $0.2 million and further reduced by a net change in operating assets and liabilities of $0.2 million. For the year ended December 31, 2022, net cash flows used in operating activities was $2.7 million (as restated), primarily consisting of a net loss of $5.0 million (as restated), decreased by a loss on change in derivative liability of $0.2 million, amortization of debt discount and finance fees of $0.4 million, a loss settlement of convertible debt of $1.7 million (as restated), a change in fair value of freestanding instruments in excess of proceeds of $0.2 million (as restated), and stock-based compensation of $0.2 million (as restated), partially offset by a gain on settlement of accounts